Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 14, 2013; 19(22): 3473-3480
Published online Jun 14, 2013. doi: 10.3748/wjg.v19.i22.3473
Figure 1
Figure 1 Correlation of overall survival with type of treatment. All 45 patients with metastatic hepatocellular carcinoma died before June, 2012. There were 21 patients in the cryo-immunotherapy group, 12 in the cryotherapy group, five in the immunotherapy group and seven in the untreated group. The overall follow-up period was 8 years. A: Overall survival (OS) of patients who underwent comprehensive cryosurgery with or without transarterial chemoembolization (TACE). Thirty-three patients were enrolled; based on the long diameter of their hepatic tumors (≥ 5 cm), 25 underwent TACE before hepatic cryoablation. Kaplan-Meier test with long-rank analysis; B: OS in the cryo-immunotherapy, cryotherapy and/or immunotherapy groups vs that in the untreated group using the Dunnett test. Horizontal lines represent the average and standard deviation. aP < 0.05, bP < 0.01 vs untreated group.
Figure 2
Figure 2 Overall survival of patients who underwent comprehensive cryosurgery with or without immunotherapy. The Kaplan-Meier test with log-rank analysis was used to compare the overall survival of 21 patients in the cryo-immunotherapy group with that of 12 patients in the cryotherapy group.
Figure 3
Figure 3 Correlation of overall survival with number of cryo- and/or immunotherapy procedures, using the Kaplan-Meier test with long-rank analysis. A: Comparison of overall survival (OS) between 10 patients who underwent repeated treatments and 11 patients who underwent a single treatment in the cryo-immunotherapy group; B: Comparison of OS between six patients who underwent repeated cryoablation and six who underwent a single cryoablation in the cryotherapy group.